Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose. Methods: Twenty-seven AML patients with normal karyotype but bearing the mutated NPM1 were enrolled in the study, and real-time quantitative PCR of NPM1-mutA was performed on 93 bone marrow (BM) samples (27 samples at diagnosis and 56 at follow-up). The NPM1-mutA allele burdens (represented as the NPM1-mutA/Abelson gene (ABL) ratio) at diagnosis and at follow-up were compared. Results: The median NPM1-mutA/ABL ratio was 1.3287 at diagnosis and 0.092 at 28 days after chemotherapy, corresponding to a median log10 reduction of 1.7061. Significant correlations were observed between BM blast counts and NPM1-mutA quantitation results measured at diagnosis (γ=0.5885, P=0.0012) and after chemotherapy (γ=0.5106, P=0.0065). Total 16 patients achieved morphologic complete remission at 28 days after chemotherapy, and 14 (87.5%) patients showed a >3 log10 reduction of the NPM1-mutA/ABL ratio. The NPM1-mutA allele was detected in each of five patients who had relapsed, giving a median increase of 0.91-fold of the NPM1-mutA/ABL ratio at relapse over that at diagnosis. Conclusions: The NPM1-mutA quantitation results corresponded to BM assessment results with high stability at relapse, and could predict patient outcomes. Quantitation of the NPM1-mutA burden at follow-up would be useful in the management of AML patients harboring this gene mutation.
Abstract
Background: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose. Methods: Twenty-seven AML patients with normal karyotype but bearing the mutated NPM1 were enrolled in the study, and real-time quantitative PCR of NPM1-mutA was performed on 93 bone marrow (BM) samples (27 samples at diagnosis and 56 at follow-up). The NPM1-mutA allele burdens (represented as the NPM1-mutA/Abelson gene (ABL) ratio) at diagnosis and at follow-up were compared. Results: The median NPM1-mutA/ABL ratio was 1.3287 at diagnosis and 0.092 at 28 days after chemotherapy, corresponding to a median log10 reduction of 1.7061. Significant correlations were observed between BM blast counts and NPM1-mutA quantitation results measured at diagnosis (γ=0.5885, P=0.0012) and after chemotherapy (γ=0.5106, P=0.0065). Total 16 patients achieved morphologic complete remission at 28 days after chemotherapy, and 14 (87.5%) patients showed a >3 log10 reduction of the NPM1-mutA/ABL ratio. The NPM1-mutA allele was detected in each of five patients who had relapsed, giving a median increase of 0.91-fold of the NPM1-mutA/ABL ratio at relapse over that at diagnosis. Conclusions: The NPM1-mutA quantitation results corresponded to BM assessment results with high stability at relapse, and could predict patient outcomes. Quantitation of the NPM1-mutA burden at follow-up would be useful in the management of AML patients harboring this gene mutation.
참고문헌 (28)
- Döhner H, "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet", Blood, 115, pp.453~474 (2010)
- Stentoft J, "Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction", Eur J Haematol, 67, pp.302~308 (2001)
- Walter RB, "Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission", Blood, 122, pp.1813~1821 (2013)
- Schnittger S, "Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML", Blood, 114, pp.2220~2231 (2009)
- Cilloni D, "Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study", J Clin Oncol, 27, pp.5195~5201 (2009)
- Krönke J, "Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group", J Clin Oncol, 29, pp.2709~2716 (2011)
- Shayegi N, "The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML", Blood, 122, pp.83~92 (2013)
- Yin JA, "Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial", Blood, 120, pp.2826~2835 (2012)
- Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview", Pathologica, 102, pp.83~87 (2010)
- Craig FE, "Flow cytometric immunophenotyping for hematologic neoplasms", Blood, 111, pp.3941~3967 (2008)
- Bene MC, "Proposals for the immunological classification of acute leukemias", Leukemia, 9, pp.1783~1786 (1995)
- Harrison CJ, "Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12", J Clin Oncol, 28, pp.2674~2681 (2010)
- Grimwade D, "The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia", Best Pract Res Clin Haematol, 14, pp.497~529 (2001)
- Mrózek K, "Cytogenetics in acute leukemia", Blood Rev, 18, pp.115~136 (2004)
- Paietta E, "Minimal residual disease in acute myeloid leukemia: coming of age", Hematology Am Soc Hematol Educ Program, 2012, pp.35~42 (2012)
- Kern W, "Monitoring of minimal residual disease in acute myeloid leukemia", Cancer, 112, pp.4~16 (2008)
- Falini B, "Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help", Haematologica, 95, pp.529~534 (2010)
- Grimwade D, "Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials", Blood, 116, pp.354~365 (2010)
- Löwenberg B, "Acute myeloid leukemia", N Engl J Med, 341, pp.1051~1062 (1999)
- Patel JP, "Prognostic relevance of integrated genetic profiling in acute myeloid leukemia", N Engl J Med, 366, pp.1079~1089 (2012)
- Ostronoff F, "Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute", Medical Research Council report, 2015, pp.33, 1157~1164
- Falini B, "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype", N Engl J Med, 352, pp.254~266 (2005)
- Gorello P, "Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations", Leukemia, 20, pp.1103~1108 (2006)
- Alpermann T, "Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia", Haematologica, 101, pp.e55~e58 (2016)
- Ivey A, "Assessment of minimal residual disease in standard-risk AML", N Engl J Med, 374, pp.422~433 (2016)
- Park SH, "CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk", Leuk Res, 37, pp.1488~1494 (2013)
- Dvorakova D, "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations", Am J Hematol, 85, pp.926~929 (2010)
- Palmisano M, "NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia", Haematologica, 92, pp.1268~1269 (2007)